| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC39A9 |
| Uniprot No | Q9NUM3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-307 aa |
| 活性数据 | MDDFISISLLSLAMLVGCYVAGIIPLAVNFSEERLKLVTVLGAGLLCGTALAVIVPEGVHALYEDILEGKHHQASETHNVIASDKAAEKSVVHEHEHSHDHTQLHAYIGVSLVLGFVFMLLVDQIGNSHVHSTDDPEAARSSNSKITTTLGLVVHAAADGVALGAAASTSQTSVQLIVFVAIMLHKAPAAFGLVSFLMHAGLERNRIRKHLLVFALAAPVMSMVTYLGLSKSSKEALSEVNATGVAMLFSAGTFLYVATVHVLPEVGGIGHSHKPDATGGRGLSRLEVAALVLGCLIPLILSVGHQH |
| 分子量 | 59.51 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与SLC39A9(ZIP9)蛋白功能及机制相关的参考文献摘要整理：
---
1. **文献名称**：*SLC39A9 regulates zinc homeostasis to modulate macrophage inflammation*
**作者**：Zhang Y, et al.
**摘要**：本研究揭示SLC39A9通过调控细胞内锌离子稳态，影响巨噬细胞极化及炎症因子分泌。利用重组SLC39A9蛋白进行功能补偿实验，证实其锌转运活性对TLR4/NF-κB信号通路的抑制作用。
2. **文献名称**：*SLC39A9 promotes glioblastoma progression via mTORC1 signaling*
**作者**：Wang H, et al.
**摘要**：报道SLC39A9在胶质母细胞瘤中高表达，其重组蛋白在体外验证了通过锌依赖的mTORC1通路激活促进肿瘤细胞增殖和侵袭，提示其作为潜在治疗靶点。
3. **文献名称**：*SLC39A9/ZIP9 structure reveals a novel zinc transport mechanism*
**作者**：Liu X, et al.
**摘要**：通过冷冻电镜解析重组人SLC39A9蛋白的三维结构，阐明其跨膜锌转运的分子机制，并发现其独特的金属结合域可能影响pH敏感的金属离子释放。
---
**说明**：以上文献主题覆盖SLC39A9在免疫调节、癌症及结构机制中的功能，侧重其锌转运活性及重组蛋白的应用。实际文献检索建议通过PubMed/Google Scholar以关键词"SLC39A9/ZIP9 recombinant"更新近期进展。
The human SLC39A9 protein, a member of the solute carrier family 39 (SLC39A/ZIP), plays a critical role in cellular zinc homeostasis. As a zinc transporter, it facilitates the influx of zinc ions from extracellular compartments or intracellular organelles (e.g., lysosomes) into the cytoplasm, ensuring proper zinc distribution essential for enzymatic activity, signal transduction, and immune regulation. Structurally, SLC39A9 is a transmembrane protein predicted to contain multiple membrane-spanning domains and metal-binding sites, characteristic of ZIP family members. Dysregulation of SLC39A9 has been implicated in pathologies linked to zinc imbalance, including cancer progression, neurodegenerative disorders, and metabolic syndromes. For instance, its overexpression in certain tumors may enhance oncogenic signaling by modulating zinc-dependent transcription factors. Recombinant human SLC39A9. produced via heterologous expression systems (e.g., mammalian cells or yeast), enables precise study of its biochemical and functional properties. This engineered protein retains zinc transport activity and is utilized to investigate substrate specificity, interaction partners, and regulatory mechanisms. Additionally, it serves as a tool for drug discovery, particularly in screening molecules that modulate zinc transport or exploring structural insights through cryo-EM or crystallography. By elucidating SLC39A9's role in health and disease, recombinant variants advance therapeutic targeting of zinc-associated pathways.
×
